Efflux transport is an important determinant of ethinylestradiol glucuronide and ethinylestradiol sulfate pharmacokinetics

Drug Metabolism and Disposition

Volumn 39, Issue 10, 2011, Pages 1794-1800

  Zamek Gliszczynski, Maciej J ^a   Day, Jeffrey S ^a   Hillgren, Kathleen M ^a   Phillips, Diane L ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

17ALPHA ETHINYLESTRADIOL 3 O GLUCURONIDE; 17ALPHA ETHINYLESTRADIOL 3 O SULFATE; BREAST CANCER RESISTANCE PROTEIN; ETHINYLESTRADIOL; MULTIDRUG RESISTANCE PROTEIN 2; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BILE; BILIARY EXCRETION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG TRANSPORT; ESTROGEN METABOLISM; GENE SILENCING; INTESTINE; INTESTINE MUCOSA PERMEABILITY; LIVER CLEARANCE; LIVER PERFUSION; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; WILD TYPE;

ADMINISTRATION, ORAL; ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; BILIARY TRACT; BIOLOGICAL TRANSPORT; CELL MEMBRANE; ESTRADIOL; ETHINYL ESTRADIOL; HALF-LIFE; INTESTINES; LIVER; MALE; MEMBRANE TRANSPORT PROTEINS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; RATS; RATS, WISTAR;

MUS; RATTUS;

EID: 80053141975     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.111.040162     Document Type: Article

References (30)

1. Back DJ, Bolt HM, Breckenridge AM, Crawford FE, Orme ML, Rowe PH, and Schindler AE (1980) The pharmacokinetics of a large (3 mg) oral dose of ethynylestradiol in women. Contraception 21:145-153. (Pubitemid 10112997)
2. Chu XY, Huskey SE, Braun MP, Sarkadi B, Evans DC, and Evers R (2004) Transport of ethinylestradiol glucuronide and ethinylestradiol sulfate by the multidrug resistance proteins MRP1, MRP2, and MRP3. J Pharmacol Exp Ther 309:156-164. (Pubitemid 38393126)
3. Davies B and Morris T (1993) Physiological parameters in laboratory animals and humans. Pharm Res 10:1093-1095. (Pubitemid 23211439)
4. Guengerich FP (1990) Metabolism of 17 alpha-ethynylestradiol in humans. Life Sci 47:1981-1988.
5. Han YH, Busler D, Hong Y, Tian Y, Chen C, and Rodrigues AD (2010a) Transporter studies with the 3-O-sulfate conjugate of 17alpha-ethinylestradiol: assessment of human kidney drug transporters. Drug Metab Dispos 38:1064-1071.
6. Han YH, Busler D, Hong Y, Tian Y, Chen C, and Rodrigues AD (2010b) Transporter studies with the 3-O-sulfate conjugate of 17alpha-ethinylestradiol: assessment of human liver drug transporters. Drug Metab Dispos 38:1072-1082.
7. Hoffmaster KA, Zamek-Gliszczynski MJ, Pollack GM, and Brouwer KL (2005) Multiple transport systems mediate the hepatic uptake and biliary excretion of the metabolically stable opioid peptide [D-penicillamine2,5]enkephalin. Drug Metab Dispos 33:287-293. (Pubitemid 40216597)
8. Hümpel M, Nieuweboer B, Wendt H, and Speck U (1979) Investigations of pharmacokinetics of ethinyloestradiol to specific consideration of a possible first-pass effect in women. Contraception 19:421-432. (Pubitemid 9153580)
9. International Transporter Consortium, Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, Chu X, Dahlin A, Evers R, Fischer V, et al. (2010) Membrane transporters in drug development. Nat Rev Drug Discov 9:215-236.
10. Johnson BM, Zhang P, Schuetz JD, and Brouwer KL (2006) Characterization of transport protein expression in multidrug resistance-associated protein (Mrp) 2-deficient rats. Drug Metab Dispos 34:556-562.
11. Kodaira H, Kusuhara H, Ushiki J, Fuse E, and Sugiyama Y (2010) Kinetic analysis of the cooperation of P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp/Abcg2) in limiting the brain and testis penetration of erlotinib, flavopiridol, and mitoxantrone. J Pharmacol Exp Ther 333:788-796.
12. Maggs JL, Grabowski PS, and Park BK (1983a) The enterohepatic circulation of the metabolites of 17 alpha-ethynyl[3H]estradiol in the rat. Xenobiotica 13:619-626. (Pubitemid 14223334)
13. Maggs JL, Grimmer SF, Orme ML, Breckenridge AM, Park BK, and Gilmore IT (1983b) The biliary and urinary metabolites of [3H]17 alpha-ethynylestradiol in women. Xenobiotica 13:421-431. (Pubitemid 13023098)
14. Murakami T and Takano M (2008) Intestinal efflux transporters and drug absorption. Expert Opin Drug Metab Toxicol 4:923-939.
15. Nezasa K, Tian X, Zamek-Gliszczynski MJ, Patel NJ, Raub TJ, and Brouwer KL (2006) Altered hepatobiliary disposition of 5 (and 6)-carboxy-2′, 7′-dichlorofluorescein in Abcg2 (Bcrp1) and Abcc2 (Mrp2) knockout mice. Drug Metab Dispos 34:718-723.
16. Rogers SM, Back DJ, Stevenson PJ, Grimmer SF, and Orme ML (1987) Paracetamol interaction with oral contraceptive steroids: increased plasma concentrations of ethinyloestradiol. Br J Clin Pharmacol 23:721-725. (Pubitemid 17087974)
17. Tsutsumi K, Li SK, Ghanem AH, Ho NF, and Higuchi WI (2003) A systematic examination of the in vitro Ussing chamber and the in situ single-pass perfusion model systems in rat ileum permeation of model solutes. J Pharm Sci 92:344-359. (Pubitemid 36169307)
18. Xiong H, Turner KC, Ward ES, Jansen PL, and Brouwer KL (2000) Altered hepatobiliary disposition of acetaminophen glucuronide in isolated perfused livers from multidrug resistance-associated protein 2-deficient TR(-) rats. J Pharmacol Exp Ther 295:512-518.
19. Xiong H, Yoshinari K, Brouwer KL, and Negishi M (2002) Role of constitutive androstane receptor in the in vivo induction of Mrp3 and CYP2B1/2 by phenobarbital. Drug Metab Dispos 30:918-923. (Pubitemid 34815422)
20. Yue W, Lee JK, Abe K, Sugiyama Y, and Brouwer KL (2011) Decreased hepatic breast cancer resistance protein expression and function in multidrug resistance-associated protein 2-deficient (TR-) rats. Drug Metab Dispos 39:441-447.
21. Zamek-Gliszczynski MJ and Brouwer KLR (2004) In vitro models for estimating hepatobiliary clearance, in Pharmaceutical Profiling in Drug Discovery for Lead Selection (Borchardt RT, Kerns EH, Lipinski CA, Thakker DR, and Wang B eds), pp 259 -292, AAPS Press, Arlington, VA.
22. Zamek-Gliszczynski MJ, Hoffmaster KA, Humphreys JE, Tian X, Nezasa K, and Brouwer KL (2006a) Differential involvement of Mrp2 (Abcc2) and Bcrp (Abcg2) in biliary excretion of 4-methylumbelliferyl glucuronide and sulfate in the rat. J Pharmacol Exp Ther 319:459-467. (Pubitemid 44455153)
23. Zamek-Gliszczynski MJ, Hoffmaster KA, Nezasa K, and Brouwer KL (2008) Apparent differences in mechanisms of harmol sulfate biliary excretion in mice and rats. Drug Metab Dispos 36:2156-2158.
24. Zamek-Gliszczynski MJ, Hoffmaster KA, Nezasa K, Tallman MN, and Brouwer KL (2006b) Integration of hepatic drug transporters and phase II metabolizing enzymes: mechanisms of hepatic excretion of sulfate, glucuronide, and glutathione metabolites. Eur J Pharm Sci 27:447-486. (Pubitemid 43363339)
25. Zamek-Gliszczynski MJ, Hoffmaster KA, Tian X, Zhao R, Polli JW, Humphreys JE, Webster LO, Bridges AS, Kalvass JC, and Brouwer KL (2005) Multiple mechanisms are involved in the biliary excretion of acetaminophen sulfate in the rat: role of Mrp2 and Bcrp1. Drug Metab Dispos 33:1158-1165. (Pubitemid 41043759)
26. Zamek-Gliszczynski MJ, Kalvass JC, Pollack GM, and Brouwer KL (2009) Relationship between drug/metabolite exposure and impairment of excretory transport function. Drug Metab Dispos 37:386-390.
27. Zamek-Gliszczynski MJ, Nezasa K, Tian X, Bridges AS, Lee K, Belinsky MG, Kruh GD, and Brouwer KL (2006c) Evaluation of the role of multidrug resistance-associated protein (Mrp) 3 and Mrp4 in hepatic basolateral excretion of sulfate and glucuronide metabolites of acetaminophen, 4-methylumbelliferone, and harmol in Abcc3-/- and Abcc4-/- mice. J Pharmacol Exp Ther 319:1485-1491.
28. Zamek-Gliszczynski MJ, Nezasa K, Tian X, Kalvass JC, Patel NJ, Raub TJ, and Brouwer KL (2006d) The important role of Bcrp (Abcg2) in the biliary excretion of sulfate and glucuronide metabolites of acetaminophen, 4-methylumbelliferone, and harmol in mice. Mol Pharmacol 70:2127-2133. (Pubitemid 44771928)
29. Zamek-Gliszczynski MJ, Xiong H, Patel NJ, Turncliff RZ, Pollack GM, and Brouwer KL (2003) Pharmacokinetics of 5 (and 6)-carboxy-2′,7′- dichlorofluorescein and its diacetate promoiety in the liver. J Pharmacol Exp Ther 304:801-809. (Pubitemid 36152359)
30. Zhang H, Cui D, Wang B, Han YH, Balimane P, Yang Z, Sinz M, and Rodrigues AD (2007) Pharmacokinetic drug interactions involving 17alpha-ethinylestradiol: a new look at an old drug. Clin Pharmacokinet 46:133-157. (Pubitemid 46193058)